Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 18, 2026
Why Is IM Cannabis Corp. (IMCC) Stock Up +166.67% Today?

Why Is IM Cannabis Corp. (IMCC) Stock Up +166.67% Today?

Key Takeaways

  • IMCC surged roughly +166.67% in Thursday's session, climbing from a prior close of $1.74 to about $4.64.
  • The rally was primarily momentum- and sentiment-driven, tied to renewed optimism around expanding legal cannabis markets.
  • A recent 30-for-1 share consolidation and a related divestiture of European assets have reshaped the company's capital structure, amplifying price volatility.
  • Volume spiked sharply, indicating heavy participation from retail and algorithmic traders.
  • Investors are watching whether the gains hold, given the stock's history of rapid, round-trip price swings.

Opening Summary

IMCC, the Nasdaq-listed common shares of IM Cannabis Corp., an international medical cannabis company with operations in Israel and Germany, posted an extraordinary single-session advance on Thursday. Shares climbed roughly 166.67%, rising from a prior closing price of $1.74 to trade near $4.64. The move marked a dramatic upward reversal for a micro-cap name that has been consolidating and restructuring in recent months. Market commentary attributed the surge primarily to a burst of speculative momentum and renewed enthusiasm around the global legal-cannabis theme, amplified by the stock's newly reduced share count and thin float.

Cannabis Sector Momentum and Legalization Optimism

The most immediate driver cited by traders was a broad lift in sentiment across the cannabis space, fueled by optimism over expanding legal-medical and adult-use markets. IM Cannabis has been leaning into growth in Germany following that country's medical cannabis liberalization, while maintaining its core Israeli medical cannabis distribution platform. When sector-wide enthusiasm builds, thinly traded small-cap cannabis names such as IMCC frequently experience outsized percentage moves, as capital rotates quickly into names perceived to offer the most leverage to a legalization catalyst.

Restructuring and Post-Consolidation Dynamics

The rally was amplified by significant recent corporate actions. The company completed a 30-for-1 share consolidation intended to support its Nasdaq listing compliance, sharply reducing the number of shares outstanding. In parallel, IM Cannabis agreed to divest its IMC Holdings and European-focused assets in a related-party transaction designed to improve shareholders' equity by roughly C$3 million and sharpen its focus on its retained Israeli medical cannabis operations. A reduced share count and a smaller effective float make the stock far more sensitive to even modest buying pressure, which helps explain the magnitude of Thursday's move.

Market Context and Trading Activity

Trading activity was exceptionally heavy, with volume running well above the stock's typical daily average. The move reflected a clear divergence from broader equity benchmarks, underscoring that it was a stock-specific, momentum-driven event rather than a reflection of general market conditions. Technically, shares blew through the multi-day consolidation range that had kept the stock in the low-to-mid single digits, recapturing levels not seen since a late-summer run. The speed and scale of the advance, however, are consistent with a "blow-off" pattern that frequently attracts day traders and momentum scanners and can reverse just as quickly.

What Comes Next for IMCC

The path forward for IMCC depends on several factors. Traders will be watching whether the company can sustain higher price levels following its restructuring, its progress in the German and Israeli medical cannabis markets, and any further developments on its Nasdaq listing compliance. Key risks include ongoing operating losses, a tight balance sheet with elevated short-term obligations, potential shareholder dilution from outstanding convertible notes, and geopolitical uncertainty in the Middle East, where the company's core operations are based. Given the stock's recent history of sharp, round-trip moves, volatility is likely to remain elevated in the near term.

Trending AI Robots

For investors seeking a more systematic approach to navigating volatile markets, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches tailored to different objectives. Consider reviewing the Trending AI Robots to see how automated strategies are adapting to today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IMCC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IMCC's Stochastic Oscillator is remaining in oversold zone for 12 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +8.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in 162 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for IMCC moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 15 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMCC as a result. In 82 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for IMCC turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 36 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

IMCC moved below its 50-day moving average on August 27, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IMCC crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

IMCC broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMCC entered a downward trend on August 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.949) is normal, around the industry mean (46.918). P/E Ratio (0.000) is within average values for comparable stocks, (93.505). IMCC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.941). IMCC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.011) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.1B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 39%. SXTC experienced the highest price growth at 26%, while GELS experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 30%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 81
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
IMCC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Details
Industry
N/A
Address
Central District
Phone
+972 773603504
Employees
44
Web
https://www.imcannabis.com
Interact to see
Advertisement
Shares of NSA stock surged roughly 27% in premarket trading after the company agreed to be acquired by Public Storage in an all-stock transaction valued at about $10.5 billion. The deal values National Storage Affiliates at an implied price of about $41.68 per share, representing a substantial premium to its prior closing price near the low-$30s.
Shares of NBIS jumped roughly 12% in premarket trading after a sharp rally in the prior regular session. The latest leg of the price rally follows news of a multibillion‑dollar, long‑term AI infrastructure agreement with Meta Platforms that expands Nebius’s cloud capacity commitments.
Micron Technology’s common stock MU (MU) rose 5.13% in the latest completed session, closing at 426.13 dollars versus 405.35 dollars previously. The move appears driven by continued enthusiasm around Micron’s role as a key memory supplier to artificial intelligence and data center markets, supporting an earnings-driven re‑rating of the stock.
IperionX Limited (IPX) is down about 15.57% in early trading on March 16, with shares recently changing hands near 29.44 dollars versus a previous close of 34.87 dollars. The drop extends a post‑earnings selloff after the company’s March 12 results highlighted continued losses and substantial funding needs to scale its titanium operations.
Shares of CTMX surged roughly 56% in the latest session, staging a sharp intraday price rally from the prior close. The move appears driven by earnings-related positioning and growing optimism around CytomX’s PROBODY therapeutic platform and late‑stage oncology pipeline.
Hyperliquid Strategies Inc (PURR) shares jumped about 15% in the latest session, extending a multi-week price rally tied to digital-asset exposure. The move comes as traders bid up proxy plays on the Hyperliquid ecosystem and HYPE token, with renewed risk appetite in crypto-related assets.
VIA fell over 11% today, extending a slide that began last week; the stock has been under pressure since trading around the high‑teens and low‑$20s, well below its $46 IPO price.
LAES fell more than 19% today as the market digested a $125 million registered direct offering of 30.4 million new shares (or pre‑funded warrants) plus warrants for up to 60.8 million additional shares, all priced at $4.11 per unit.
Shares of ALDX are down about 73.02% in premarket trading, plunging from a prior close near 4.13 dollars to roughly 1.11 dollars after a major regulatory setback. The collapse follows fresh confirmation that the U.S. Food and Drug Administration has again declined to approve reproxalap for dry eye disease, issuing another Complete Response Letter that questions efficacy.
Shares of MVST are down about 25% in premarket trading today compared with the prior close. The slide follows a sharp reassessment of the company’s outlook as investors react to new information and recent volatility in high‑beta battery and EV names.
Solaris Energy Infrastructure’s stock SEI jumped roughly 13% in today’s session, extending a sharp recent rebound from early-March lows. The move is driven by ongoing post-earnings momentum after strong Q4 and full‑year 2025 results and raised guidance highlighted rapid growth in its power solutions business.
Shares of LMND are trading approximately +10% higher intraday on Tuesday, March 17, 2026, rising from a prior close of $57.74 to around $63.51. Primary catalyst: Morgan Stanley upgraded LMND to an 'Overweight' rating and raised its price target to $85 from $80.
Shares of ICHR surged approximately +15% intraday on Tuesday, March 17, 2026, trading near $48.98 versus a prior closing price of $42.59. The primary catalyst is a high-profile analyst upgrade by Stifel, with analyst Brian Chin upgrading the stock to Buy citing improved cyclical strength and conviction in the company's revenue and margin trajectory.
NBIS shares are down approximately 10.00% in Tuesday's session, falling from a prior close of $129.85 to around $116.87. The primary catalyst is Nebius Group's pre-market announcement of a proposed $3.75 billion convertible senior notes offering, sparking dilution concerns.
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.